COMMUNIQUÉS West-GlobeNewswire
-
Cronos Brings Back Popular, Limited-Edition Spinach® Green Apple-Flavored Products for the Fall Season
28/10/2025 -
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
28/10/2025 -
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
28/10/2025 -
Context Therapeutics to Participate in Upcoming Investor Conferences
28/10/2025 -
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
28/10/2025 -
Evidence Against Evidence: CERN-IEEE FPGA vs. Crosetto 3D-Flow, a Breakthrough Invention Recognized 32 Years Ago That Could Have, and Can Still, Save Billions of Euros and Millions of Lives
28/10/2025 -
BioNTech to Host Innovation Series R&D Day on November 11, 2025
28/10/2025 -
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
28/10/2025 -
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
28/10/2025 -
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
28/10/2025 -
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
28/10/2025 -
Novartis announces expiration of Tourmaline Bio tender offer
28/10/2025 -
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers
28/10/2025 -
Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines
28/10/2025 -
Présentation du tout premier grand modèle de langage multiomique au monde au salon Global Health Exhibition de Riyad, ou la promesse d’un décodage du langage de la biologie humaine
28/10/2025 -
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
28/10/2025 -
Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome
28/10/2025 -
Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts obligataires
28/10/2025 -
Press release: Sanofi successfully prices USD 3 billion of bond issue
28/10/2025
Pages